Clustering O
of O
missense O
mutations O
in O
the O
ataxia B
- I
telangiectasia I
gene O
in O
a O
sporadic B
T I
- I
cell I
leukaemia I
. O

Ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
is O
a O
recessive B
multi I
- I
system I
disorder I
caused O
by O
mutations O
in O
the O
ATM O
gene O
at O
11q22 O
- O
q23 O
( O
ref O
. O
3 O
) O
. O

Ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
is O
a O
recessive B
multi I
- I
system I
disorder I
caused O
by O
mutations O
in O
the O
ATM O
gene O
at O
11q22 O
- O
q23 O
( O
ref O
. O
3 O
) O
. O

The O
risk O
of O
cancer B
, O
especially O
lymphoid B
neoplasias I
, O
is O
substantially O
elevated O
in O
A B
- I
T I
patients O
and O
has O
long O
been O
associated O
with O
chromosomal O
instability O
. O

By O
analysing O
tumour B
DNA O
from O
patients O
with O
sporadic B
T I
- I
cell I
prolymphocytic I
leukaemia I
( O
T B
- I
PLL I
) O
, O
a O
rare O
clonal B
malignancy I
with O
similarities O
to O
a O
mature B
T I
- I
cell I
leukaemia I
seen O
in O
A B
- I
T I
, O
we O
demonstrate O
a O
high O
frequency O
of O
ATM O
mutations O
in O
T B
- I
PLL I
. O

By O
analysing O
tumour B
DNA O
from O
patients O
with O
sporadic B
T I
- I
cell I
prolymphocytic I
leukaemia I
( O
T B
- I
PLL I
) O
, O
a O
rare O
clonal B
malignancy I
with O
similarities O
to O
a O
mature B
T I
- I
cell I
leukaemia I
seen O
in O
A B
- I
T I
, O
we O
demonstrate O
a O
high O
frequency O
of O
ATM O
mutations O
in O
T B
- I
PLL I
. O

By O
analysing O
tumour B
DNA O
from O
patients O
with O
sporadic B
T I
- I
cell I
prolymphocytic I
leukaemia I
( O
T B
- I
PLL I
) O
, O
a O
rare O
clonal B
malignancy I
with O
similarities O
to O
a O
mature B
T I
- I
cell I
leukaemia I
seen O
in O
A B
- I
T I
, O
we O
demonstrate O
a O
high O
frequency O
of O
ATM O
mutations O
in O
T B
- I
PLL I
. O

In O
marked O
contrast O
to O
the O
ATM O
mutation O
pattern O
in O
A B
- I
T I
, O
the O
most O
frequent O
nucleotide O
changes O
in O
this O
leukaemia B
were O
missense O
mutations O
. O

Two O
of O
seventeen O
mutated O
T B
- I
PLL I
samples O
had O
a O
previously O
reported O
A B
- I
T I
allele O
. O

Two O
of O
seventeen O
mutated O
T B
- I
PLL I
samples O
had O
a O
previously O
reported O
A B
- I
T I
allele O
. O

Occasional O
missense O
mutations O
in O
ATM O
were O
also O
found O
in O
tumour B
DNA O
from O
patients O
with O
B B
- I
cell I
non I
- I
Hodgkins I
lymphomas I
( O
B B
- I
NHL I
) O
and O
a O
B B
- I
NHL I
cell O
line O
. O

Occasional O
missense O
mutations O
in O
ATM O
were O
also O
found O
in O
tumour B
DNA O
from O
patients O
with O
B B
- I
cell I
non I
- I
Hodgkins I
lymphomas I
( O
B B
- I
NHL I
) O
and O
a O
B B
- I
NHL I
cell O
line O
. O

As O
constitutional O
DNA O
was O
not O
available O
, O
a O
putative O
hereditary O
predisposition O
to O
T B
- I
PLL I
will O
require O
further O
investigation O
. O
. O

The O
proband O
, O
a O
20 O
- O
year O
- O
old O
black O
female O
with O
systemic B
lupus I
erythematosus I
since O
age O
11 O
, O
lacked O
serum O
hemolytic O
complement O
activity O
, O
even O
during O
remission O
. O

Normal O
hemolytic O
titers O
were O
restored O
to O
both O
homozygous O
C5 B
- I
deficient I
( O
C5D B
) O
sera O
by O
addition O
of O
highly O
purified O
human O
C5 O
. O

This O
mutation O
may O
be O
valuable O
for O
developing O
models O
of O
dominantly B
inherited I
neurodegeneration I
, O
as O
the O
early O
age O
of O
onset O
of O
symptoms O
suggests O
that O
this O
mutation O
may O
be O
particularly O
deleterious O
to O
the O
magnocellular O
neuron O
. O
. O

Sporadic B
prostate I
carcinoma I
is O
the O
most O
common O
male B
cancer I
in O
the O
Western O
world O
, O
yet O
many O
of O
the O
major O
genetic O
events O
involved O
in O
the O
progression O
of O
this O
often O
fatal O
cancer B
remain O
to O
be O
elucidated O
. O

Numerous O
cytogenetic O
and O
allelotype O
studies O
have O
reported O
frequent O
loss O
of O
heterozygosity O
on O
chromosomal O
arm O
10q O
in O
sporadic B
prostate I
cancer I
. O

The O
identification O
of O
the O
second O
mutational O
event O
in O
10 O
( O
43 O
% O
) O
tumors B
establishes O
PTEN O
/ O
MMAC1 O
as O
a O
main O
inactivation O
target O
of O
10q O
loss O
in O
sporadic B
prostate I
cancer I
. O
. O

Paternal O
transmission O
of O
congenital B
myotonic I
dystrophy I
. O

We O
report O
a O
rare O
case O
of O
paternally O
transmitted O
congenital B
myotonic I
dystrophy I
( O
DM B
) O
. O

The O
RB1 O
gene O
mutation O
in O
a O
child O
with O
ectopic B
intracranial I
retinoblastoma I
. O

The O
RB1 O
gene O
mutation O
was O
investigated O
in O
a O
child O
with O
ectopic B
intracranial I
retinoblastoma I
using O
DNA O
obtained O
from O
both O
the O
pineal B
and I
retinal I
tumours I
of O
the O
patient O
. O

However O
, O
direct O
visualization O
and O
quantitation O
of O
hex O
A O
by O
the O
methods O
described O
may O
prevent O
false O
- O
positive O
prenatal O
diagnosis O
of O
TSD B
in O
fetuses O
having O
the O
incomplete O
hex B
A I
deficiency I
of O
the O
type O
described O
in O
the O
four O
healthy O
individuals O

Detection O
of O
heterozygous O
carriers O
of O
the O
ataxia B
- I
telangiectasia I
( O
ATM O
) O
gene O
by O
G2 O
phase O
chromosomal O
radiosensitivity O
of O
peripheral O
blood O
lymphocytes O
. O

In O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
ATM O
, O
result O
in O
an O
autosomal B
recessive I
syndrome I
that O
embraces O
a O
variety O
of O
clinical O
features O
and O
manifests O
extreme O
radiosensitivity O
and O
a O
strong O
pre O
- O
disposition O
to O
malignancy B
. O

In O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
ATM O
, O
result O
in O
an O
autosomal B
recessive I
syndrome I
that O
embraces O
a O
variety O
of O
clinical O
features O
and O
manifests O
extreme O
radiosensitivity O
and O
a O
strong O
pre O
- O
disposition O
to O
malignancy B
. O

In O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
ATM O
, O
result O
in O
an O
autosomal B
recessive I
syndrome I
that O
embraces O
a O
variety O
of O
clinical O
features O
and O
manifests O
extreme O
radiosensitivity O
and O
a O
strong O
pre O
- O
disposition O
to O
malignancy B
. O

Heterozygotes O
for O
the O
ATM O
gene O
have O
no O
clinical O
expression O
of O
A B
- I
T I
but O
may O
be O
cancer B
prone O
with O
a O
moderate O
increase O
in O
in O
vitro O
radiosensitivity O
. O

We O
performed O
a O
blind O
chromosomal O
analysis O
on O
G2 O
- O
phase O
lymphocytes O
from O
7 O
unrelated O
A B
- I
T I
patients O
, O
13 O
obligate O
A B
- I
T I
heterozygotes O
( O
parents O
of O
the O
patients O
) O
, O
and O
14 O
normal O
controls O
following O
X O
- O
irradiation O
with O
1 O
Gy O
in O
order O
to O
evaluate O
this O
cytogenetic O
method O
as O
a O
tool O
for O
detection O
of O
ATM O
carriers O
. O

We O
performed O
a O
blind O
chromosomal O
analysis O
on O
G2 O
- O
phase O
lymphocytes O
from O
7 O
unrelated O
A B
- I
T I
patients O
, O
13 O
obligate O
A B
- I
T I
heterozygotes O
( O
parents O
of O
the O
patients O
) O
, O
and O
14 O
normal O
controls O
following O
X O
- O
irradiation O
with O
1 O
Gy O
in O
order O
to O
evaluate O
this O
cytogenetic O
method O
as O
a O
tool O
for O
detection O
of O
ATM O
carriers O
. O

Both O
A B
- I
T I
homozygotes O
and O
heterozygotes O
showed O
significantly O
increased O
levels O
of O
radiation O
- O
induced O
chromatid O
damage O
relative O
to O
that O
of O
normal O
controls O
. O

These O
results O
show O
that O
the O
G2 O
- O
phase O
chromosomal O
radiosensitivity O
assay O
can O
be O
used O
for O
the O
detection O
of O
A B
- I
T I
heterozygotes O
. O

Ataxia B
- I
telangiectasia I
: O
identification O
and O
detection O
of O
founder O
- O
effect O
mutations O
in O
the O
ATM O
gene O
in O
ethnic O
populations O
. O

To O
facilitate O
the O
evaluation O
of O
ATM O
heterozygotes O
for O
susceptibility O
to O
other O
diseases O
, O
such O
as O
breast B
cancer I
, O
we O
have O
attempted O
to O
define O
the O
most O
common O
mutations O
and O
their O
frequencies O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
homozygotes O
from O
10 O
ethnic O
populations O
. O

To O
facilitate O
the O
evaluation O
of O
ATM O
heterozygotes O
for O
susceptibility O
to O
other O
diseases O
, O
such O
as O
breast B
cancer I
, O
we O
have O
attempted O
to O
define O
the O
most O
common O
mutations O
and O
their O
frequencies O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
homozygotes O
from O
10 O
ethnic O
populations O
. O

These O
assays O
should O
facilitate O
screening O
for O
A B
- I
T I
heterozygotes O
in O
the O
populations O
studied O
. O
. O

The O
inactivation O
of O
the O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
tumor I
suppressor O
gene O
predisposes O
affected O
individuals O
to O
the O
human O
VHL B
cancer I
syndrome I
and O
is O
associated O
with O
sporadic B
renal I
cell I
carcinomas I
( O
RCC B
) O
and O
brain B
hemangioblastomas I
. O

Patients O
with O
generalized O
atrophic B
benign I
epidermolysis I
bullosa I
, O
a O
usually O
nonlethal O
form O
of O
junctional B
epidermolysis I
bullosa I
, O
have O
generalized O
blistering B
, O
nail B
dystrophy I
, O
patchy B
alopecia I
, O
and O
dental B
abnormalities I
. O

ATM O
mutations O
and O
phenotypes O
in O
ataxia B
- I
telangiectasia I
families O
in O
the O
British O
Isles O
: O
expression O
of O
mutant O
ATM O
and O
the O
risk O
of O
leukemia B
, O
lymphoma B
, O
and O
breast B
cancer I
. O

We O
report O
the O
spectrum O
of O
59 O
ATM O
mutations O
observed O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
patients O
in O
the O
British O
Isles O
. O

We O
report O
the O
spectrum O
of O
59 O
ATM O
mutations O
observed O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
patients O
in O
the O
British O
Isles O
. O

We O
report O
, O
in O
two O
A B
- I
T I
families O
, O
an O
ATM O
mutation O
( O
7271T O
- O
- O
> O
G O
) O
that O
may O
be O
associated O
with O
an O
increased O
risk O
of O
breast B
cancer I
in O
both O
homozygotes O
and O
heterozygotes O
( O
relative O
risk O
12 O
. O
7 O
; O
P O
= O
. O
0025 O
) O
, O
although O
there O
is O
a O
less O
severe O
A B
- I
T I
phenotype O
in O
terms O
of O
the O
degree O
of O
cerebellar B
degeneration I
. O

We O
report O
, O
in O
two O
A B
- I
T I
families O
, O
an O
ATM O
mutation O
( O
7271T O
- O
- O
> O
G O
) O
that O
may O
be O
associated O
with O
an O
increased O
risk O
of O
breast B
cancer I
in O
both O
homozygotes O
and O
heterozygotes O
( O
relative O
risk O
12 O
. O
7 O
; O
P O
= O
. O
0025 O
) O
, O
although O
there O
is O
a O
less O
severe O
A B
- I
T I
phenotype O
in O
terms O
of O
the O
degree O
of O
cerebellar B
degeneration I
. O

In O
addition O
, O
we O
have O
studied O
18 O
A B
- I
T I
patients O
, O
in O
15 O
families O
, O
who O
developed O
leukemia B
, O
lymphoma B
, O
preleukemic O
T O
- O
cell O
proliferation O
, O
or O
Hodgkin B
lymphoma I
, O
mostly O
in O
childhood O
. O

We O
also O
show O
that O
25 O
% O
of O
all O
A B
- I
T I
patients O
carried O
in O
- O
frame O
deletions O
or O
missense O
mutations O
, O
many O
of O
which O
were O
also O
associated O
with O
expression O
of O
mutant O
ATM O
protein O
. O

Specifically O
and O
more O
directly O
, O
an O
association O
was O
also O
observed O
between O
the O
presence O
of O
a O
PTEN O
mutation O
and O
malignant B
breast I
disease I
. O

Mutations O
in O
PAX6 O
are O
responsible O
for O
human O
aniridia B
and O
have O
also O
been O
found O
in O
patients O
with O
Peters B
anomaly I
, O
with O
congenital B
cataracts I
, O
with O
autosomal B
dominant I
keratitis I
, O
and O
with O
isolated B
foveal I
hypoplasia I
. O

Mutations O
in O
PAX6 O
are O
responsible O
for O
human O
aniridia B
and O
have O
also O
been O
found O
in O
patients O
with O
Peters B
anomaly I
, O
with O
congenital B
cataracts I
, O
with O
autosomal B
dominant I
keratitis I
, O
and O
with O
isolated B
foveal I
hypoplasia I
. O

The O
contribution O
of O
BRCA1 O
and O
BRCA2 O
to O
inherited B
breast I
cancer I
was O
assessed O
by O
linkage O
and O
mutation O
analysis O
in O
237 O
families O
, O
each O
with O
at O
least O
four O
cases O
of O
breast B
cancer I
, O
collected O
by O
the O
Breast B
Cancer I
Linkage O
Consortium O
. O

Eye B
movement I
abnormalities I
correlate O
with O
genotype O
in O
autosomal O
dominant O
cerebellar B
ataxia I
type I
I I
. O

Genetic O
basis O
and O
molecular O
mechanism O
for O
idiopathic B
ventricular I
fibrillation I
. O

In O
approximately O
5 O
- O
12 O
% O
of O
these O
cases O
, O
there O
are O
no O
demonstrable O
cardiac O
or O
non O
- O
cardiac O
causes O
to O
account O
for O
the O
episode O
, O
which O
is O
therefore O
classified O
as O
idiopathic B
ventricular I
fibrillation I
( O
IVF B
) O
. O

Identification O
of O
constitutional O
WT1 O
mutations O
, O
in O
patients O
with O
isolated O
diffuse B
mesangial I
sclerosis I
, O
and O
analysis O
of O
genotype O
/ O
phenotype O
correlations O
by O
use O
of O
a O
computerized O
mutation O
database O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B
- I
Drash I
syndrome I
( O
DDS B
) O
, O
or O
diffuse B
mesangial I
sclerosis I
( O
DMS B
) O
associated O
with O
pseudohermaphroditism B
and O
/ O
or O
Wilms B
tumor I
( O
WT B
) O
. O

Familial B
neurohypophyseal I
diabetes I
insipidus I
( O
FNDI B
) O
is O
an O
autosomal B
dominant I
disease I
caused O
by O
deficiency O
in O
the O
antidiuretic O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
encoded O
by O
the O
AVP O
- O
neurophysin O
II O
( O
AVP O
- O
NPII O
) O
gene O
on O
chromosome O
20p13 O
. O

Thirty O
- O
two O
unrelated O
patients O
with O
features O
of O
Saethre B
- I
Chotzen I
syndrome I
, O
a O
common O
autosomal B
dominant I
condition I
of O
craniosynostosis B
and O
limb B
anomalies I
, O
were O
screened O
for O
mutations O
in O
TWIST O
, O
FGFR2 O
, O
and O
FGFR3 O
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
TWIST O
mutations O
, O
are O
coronal B
synostosis I
, O
brachycephaly B
, O
low B
frontal I
hairline I
, O
facial B
asymmetry I
, O
ptosis B
, O
hypertelorism B
, O
broad B
great I
toes I
, O
and O
clinodactyly B
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
TWIST O
mutations O
, O
are O
coronal B
synostosis I
, O
brachycephaly B
, O
low B
frontal I
hairline I
, O
facial B
asymmetry I
, O
ptosis B
, O
hypertelorism B
, O
broad B
great I
toes I
, O
and O
clinodactyly B
. O

Germ O
- O
line O
mutations O
of O
the O
tumor B
suppressor O
APC O
are O
implicated O
in O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
, O
a O
variant O
of O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
. O

Wilms B
' I
tumor I
1 O
and O
Dax O
- O
1 O
modulate O
the O
orphan O
nuclear O
receptor O
SF O
- O
1 O
in O
sex O
- O
specific O
gene O
expression O
. O

Mutations O
of O
the O
ATM O
gene O
detected O
in O
Japanese O
ataxia B
- I
telangiectasia I
patients O
: O
possible O
preponderance O
of O
the O
two O
founder O
mutations O
4612del165 O
and O
7883del5 O
. O

3 O
has O
recently O
been O
identified O
as O
the O
gene O
responsible O
for O
the O
human O
recessive B
disease I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
. O

3 O
has O
recently O
been O
identified O
as O
the O
gene O
responsible O
for O
the O
human O
recessive B
disease I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
. O

In O
order O
to O
define O
the O
types O
of O
disease O
- O
causing O
ATM O
mutations O
in O
Japanese O
A B
- I
T I
patients O
as O
well O
as O
to O
look O
for O
possible O
mutational O
hotspots O
, O
reverse O
- O
transcribed O
RNA O
derived O
from O
ten O
patients O
belonging O
to O
eight O
unrelated O
Japanese O
A B
- I
T I
families O
was O
analyzed O
for O
mutations O
by O
the O
restriction O
endonuclease O
fingerprinting O
method O
. O

In O
order O
to O
define O
the O
types O
of O
disease O
- O
causing O
ATM O
mutations O
in O
Japanese O
A B
- I
T I
patients O
as O
well O
as O
to O
look O
for O
possible O
mutational O
hotspots O
, O
reverse O
- O
transcribed O
RNA O
derived O
from O
ten O
patients O
belonging O
to O
eight O
unrelated O
Japanese O
A B
- I
T I
families O
was O
analyzed O
for O
mutations O
by O
the O
restriction O
endonuclease O
fingerprinting O
method O
. O

The O
resulting O
W474C O
substitution O
clearly O
interferes O
with O
alpha O
- O
subunit O
processing O
, O
but O
because O
the O
base O
substitution O
falls O
at O
the O
first O
position O
of O
exon O
13 O
, O
aberrant O
splicing O
may O
also O
contribute O
to O
Hex B
A I
deficiency I
in O
this O
proband O
. O
. O

Pendred B
syndrome I
is O
an O
autosomal B
recessive I
disorder I
characterized O
by O
early O
childhood O
deafness B
and O
goiter B
. O

To O
date O
, O
several O
mutations O
in O
the O
Duchenne B
muscular I
dystrophy I
gene O
, O
DMD O
, O
have O
been O
identified O
in O
patients O
with O
XLDCM B
, O
but O
a O
pathogenic O
correlation O
of O
these O
cardiospecific O
mutations O
in O
DMD O
with O
the O
XLDCM B
phenotype O
has O
remained O
to O
be O
elucidated O
. O

These O
findings O
represent O
the O
first O
examples O
of O
a O
genetic B
defect I
within O
the O
POMC O
gene O
and O
define O
a O
new O
monogenic B
endocrine I
disorder I
resulting O
in O
early O
- O
onset O
obesity B
, O
adrenal B
insufficiency I
and O
red O
hair O
pigmentation O
. O
. O

A O
European O
multicenter O
study O
of O
phenylalanine B
hydroxylase I
deficiency I
: O
classification O
of O
105 O
mutations O
and O
a O
general O
system O
for O
genotype O
- O
based O
prediction O
of O
metabolic O
phenotype O
. O

We O
report O
on O
an O
unusual O
case O
of O
maternal B
disomy I
15 I
in O
PWS B
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
with O
simultaneous O
maternal O
meiotic O
nondisjunction O
for O
chromosome O
15 O
. O

Furthermore O
, O
our O
findings O
are O
best O
interpreted O
as O
true O
gamete O
complementation O
resulting O
in O
maternal B
UPD I
15 I
and O
PWS B

Recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
) O
of O
myotonia B
and O
skeletal B
dysplasia I
, O
which O
we O
called O
SJS B
type I
2 I
. O

To O
test O
for O
possible O
nosologic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
SJS B
type I
2 I
at O
age O
10 O
years O
and O
another O
with O
SWS B
at O
age O
7 O
years O
. O

Patients O
reported O
as O
having O
either O
neonatal O
SJS B
or O
SWS B
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B
disorder I
( O
with O
congenital B
joint I
contractures I
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B
- I
metaphyseal I
skeletal I
dysplasia I
. O

The O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B
dysplasia I
in O
the O
two O
patients O
( O
one O
with O
SJS B
type I
2 I
, O
one O
with O
SWS B
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

The O
hypothesis O
that O
SWS B
and O
SJS B
type I
2 I
are O
the O
same O
disorder O
should O
be O
testable O
by O
molecular O
methods O
. O
. O

A O
mouse O
model O
of O
severe O
von B
Willebrand I
disease I
: O
defects O
in O
hemostasis O
and O
thrombosis B
. O

von B
Willebrand I
factor I
( I
vWf I
) I
deficiency I
causes O
severe O
von B
Willebrand I
disease I
in O
humans O
. O

vWf B
- I
deficient I
mice O
appeared O
normal O
at O
birth O
; O
they O
were O
viable O
and O
fertile O
. O

We O
conclude O
that O
these O
mice O
very O
closely O
mimic O
severe O
human O
von B
Willebrand I
disease I
and O
will O
be O
very O
useful O
for O
investigating O
the O
role O
of O
vWf O
in O
normal O
physiology O
and O
in O
disease O
models O
. O
. O

Oral O
contraceptives O
and O
the O
risk O
of O
hereditary B
ovarian I
cancer I
. O

Hereditary B
Ovarian I
Cancer I
Clinical O
Study O
Group O
. O

METHODS O
We O
enrolled O
207 O
women O
with O
hereditary B
ovarian I
cancer I
and O
161 O
of O
their O
sisters O
as O
controls O
in O
a O
case O
- O
control O
study O
. O

Nonsense O
mutation O
in O
exon O
4 O
of O
human O
complement O
C9 O
gene O
is O
the O
major O
cause O
of O
Japanese O
complement B
C9 I
deficiency I
. O

We O
studied O
the O
molecular O
basis O
of O
C9 B
deficiency I
in O
four O
Japanese O
C9 B
- I
deficient I
patients O
who O
had O
suffered O
from O
meningococcal B
meningitis I
. O

Direct O
sequencing O
of O
amplified O
C9 O
cDNA O
and O
DNA O
revealed O
a O
nonsense O
substitution O
( O
CGA O
- O
- O
> O
TGA O
) O
at O
codon O
95 O
in O
exon O
4 O
in O
the O
four O
C9 B
- I
deficient I
individuals O
. O

Here O
, O
it O
is O
shown O
that O
mouse O
embryonic O
stem O
cells O
deficient B
in I
BRCA1 I
are O
defective O
in O
the O
ability O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
oxidative O
DNA O
damage O
, O
and O
are O
hypersensitive O
to O
ionizing O
radiation O
and O
hydrogen O
peroxide O
. O

Heterozygous O
mutations O
in O
the O
human O
PAX6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B
, O
Peters B
anomaly I
, O
autosomal B
dominant I
keratitis I
, O
and O
familial B
foveal I
dysplasia I
. O

Heterozygous O
mutations O
in O
the O
human O
PAX6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B
, O
Peters B
anomaly I
, O
autosomal B
dominant I
keratitis I
, O
and O
familial B
foveal I
dysplasia I
. O

Classical O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
high O
- O
penetrance O
autosomal B
dominant I
disease I
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B
adenomas I
and I
carcinoma I
and O
that O
results O
from O
truncating O
mutations O
in O
the O
APC B
gene O
. O

Classical O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
a O
high O
- O
penetrance O
autosomal B
dominant I
disease I
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B
adenomas I
and I
carcinoma I
and O
that O
results O
from O
truncating O
mutations O
in O
the O
APC B
gene O
. O

Genomic O
structure O
of O
the O
human O
congenital B
chloride I
diarrhea I
( O
CLD B
) O
gene O
. O

Congenital B
chloride I
diarrhea I
( O
CLD B
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
encodes O
an O
intestinal O
anion O
transporter O
. O

Mutations O
in O
APC O
are O
classically O
associated O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
a O
highly O
penetrant O
autosomal B
dominant I
disorder I
characterized O
by O
multiple O
intestinal O
polyps B
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B
cancer I
( O
CRC B
) O
. O

Mutations O
in O
APC O
are O
classically O
associated O
with O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
, O
a O
highly O
penetrant O
autosomal B
dominant I
disorder I
characterized O
by O
multiple O
intestinal O
polyps B
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B
cancer I
( O
CRC B
) O
. O

To O
discover O
genes O
involved O
in O
von B
Hippel I
- I
Lindau I
( O
VHL B
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B
cell I
carcinoma I
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
VHL O
- O
expressing O
transgenes O
. O

Reintroduced O
wild O
- O
type O
VHL B
strongly O
inhibited O
the O
overexpression O
of O
the O
CA12 O
gene O
in O
the O
parental O
renal B
cell I
carcinoma I
cell O
lines O
. O

ATM O
germline O
mutations O
in O
classical O
ataxia B
- I
telangiectasia I
patients O
in O
the O
Dutch O
population O
. O

Germline O
mutations O
in O
the O
ATM O
gene O
are O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
. O

Germline O
mutations O
in O
the O
ATM O
gene O
are O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
. O

Germline O
mutations O
in O
the O
ATM O
gene O
are O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
. O

In O
our O
study O
, O
we O
have O
determined O
the O
ATM O
mutation O
spectrum O
in O
19 O
classical O
A B
- I
T I
patients O
, O
including O
some O
immigrant O
populations O
, O
as O
well O
as O
12 O
of O
Dutch O
ethnic O
origin O
. O

The O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
Turkish O
A B
- I
T I
individuals O
, O
was O
previously O
described O
to O
be O
a O
Turkish O
A B
- I
T I
founder O
mutation O
. O

The O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
Turkish O
A B
- I
T I
individuals O
, O
was O
previously O
described O
to O
be O
a O
Turkish O
A B
- I
T I
founder O
mutation O
. O

All O
patients O
manifested O
classical O
A B
- I
T I
and O
increased O
cellular O
radioresistant O
DNA O
synthesis O
. O

Are O
Dp71 O
and O
Dp140 O
brain O
dystrophin O
isoforms O
related O
to O
cognitive B
impairment I
in O
Duchenne B
muscular I
dystrophy I
? O

Molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
Duchenne B
muscular I
dystrophy I
( O
DMD B
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B
impairment I
observed O
in O
most O
DMD B
patients O
. O

Hereditary B
coproporphyria I
( O
HCP B
) O
is O
an O
autosomal B
dominant I
disease I
characterized O
by O
a O
deficiency B
of I
coproporphyrinogen I
oxidase I
( O
CPO O
) O
caused O
by O
a O
mutation O
in O
the O
CPO O
gene O
. O

Human B
complement I
factor I
H I
deficiency I
associated O
with O
hemolytic B
uremic I
syndrome I
. O

This O
study O
reports O
on O
six O
cases O
of O
deficiency B
in I
the I
human I
complement I
regulatory I
protein I
Factor I
H I
( O
FH O
) O
in O
the O
context O
of O
an O
acute B
renal I
disease I
. O

Five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
idiopathic O
hemolytic B
uremic I
syndrome I
( O
HUS B
) O
. O

Factor B
H I
deficiency I
is O
the O
only O
complement B
deficiency I
associated O
with O
HUS B
. O

We O
have O
also O
observed O
the O
879delG O
defect O
in O
two O
Dutch O
C6 B
- I
deficient I
kindreds O
, O
but O
the O
879delG O
defect O
in O
the O
Cape O
probably O
did O
not O
come O
from O
The O
Netherlands O
. O
. O

Complement B
C7 I
deficiency I
: O
seven O
further O
molecular O
defects O
and O
their O
associated O
marker O
haplotypes O
. O

A O
genome O
- O
wide O
search O
for O
chromosomal O
loci O
linked O
to O
mental O
health O
wellness O
in O
relatives O
at O
high O
risk O
for O
bipolar B
affective I
disorder I
among O
the O
Old O
Order O
Amish O
. O

Bipolar B
affective I
disorder I
( O
BPAD B
; O
manic B
- I
depressive I
illness I
) O
is O
characterized O
by O
episodes O
of O
mania B
and O
/ O
or O
hypomania B
interspersed O
with O
periods O
of O
depression B
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disease I
which O
, O
in O
the O
typical O
pedigree O
, O
shows O
a O
three O
generation O
anticipation O
cascade O
. O

This O
results O
in O
infertility B
and O
congenital B
myotonic I
dystrophy I
( O
CDM B
) O
with O
the O
disappearance O
of O
DM B
in O
that O
pedigree O
. O

Human O
MLH1 O
deficiency O
predisposes O
to O
hematological B
malignancy I
and O
neurofibromatosis B
type I
1 I
. O

We O
have O
identified O
three O
offspring O
in O
a O
hereditary B
nonpolyposis I
colorectal I
cancer I
family O
who O
developed O
hematological B
malignancy I
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B
type I
1 I
( O
NF1 B
) O
. O

Thus O
, O
a O
homozygous O
germ O
- O
line O
MLH1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B
and O
/ O
or O
lymphoma B
associated O
with O
neurofibromatosis B
type I
1 I
. O
. O

Missense O
mutations O
in O
the O
most O
ancient O
residues O
of O
the O
PAX6 O
paired O
domain O
underlie O
a O
spectrum O
of O
human O
congenital B
eye I
malformations I
. O

Abnormal O
hepatic B
copper I
accumulation I
is O
recognized O
as O
an O
inherited B
disorder I
in O
man O
, O
mouse O
, O
rat O
and O
dog O
. O

The O
major O
cause O
of O
hepatic B
copper I
accumulation I
in O
man O
is O
a O
dysfunctional O
ATP7B O
gene O
, O
causing O
Wilson B
disease I
( O
WD B
) O
. O

BACKGROUND O
/ O
AIMS O
The O
development O
of O
colorectal B
cancer I
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
mutations O
. O

BACKGROUND O
/ O
AIMS O
The O
development O
of O
colorectal B
cancer I
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
mutations O
. O

Inherited B
colorectal I
polyposis I
and O
cancer B
risk O
of O
the O
APC O
I1307K O
polymorphism O
. O

To O
assess O
the O
risk O
of O
this O
common O
APC B
allelic O
variant O
in O
colorectal O
carcinogenesis O
, O
we O
have O
analyzed O
a O
large O
cohort O
of O
unselected O
Ashkenazi O
Jewish O
subjects O
with O
adenomatous B
polyps I
and O
. O
or O
colorectal B
cancer I
, I
for O
the O
APC O
I1307K O
polymorphism O
. O

Immunohistochemical O
staining O
of O
human O
breast O
specimens O
also O
revealed O
BRCA1 O
nuclear O
foci O
in O
benign O
breast O
, O
invasive B
lobular I
cancers I
and O
low B
- I
grade I
ductal I
carcinomas I
. O

Conversely O
, O
BRCA1 O
expression O
was O
reduced O
or O
undetectable O
in O
the O
majority O
of O
high O
- O
grade O
, O
ductal B
carcinomas I
, O
suggesting O
that O
absence O
of O
BRCA1 O
may O
contribute O
to O
the O
pathogenesis O
of O
a O
significant O
percentage O
of O
sporadic B
breast I
cancers I
. O
. O

